Showing results (211-220 of 536) with videos related to
Sort By:
Pageof 54
Expert Opinion on Pharmacotherapy|May 6, 2022
Recent advances in the pharmacotherapeutic management of diabetic kidney diseaseTomasz J Block, Duygu Batu, Mark E CooperPhysiological Reports|March 18, 2015
Pathological hypertrophy reverses β2-adrenergic receptor-induced angiogenesis in mouse heartQi Xu, Nicole L Jennings, Kenneth Sim, et al.Science Advances|April 1, 2021
Processed foods drive intestinal barrier permeability and microvascular diseasesMatthew Snelson, Sih Min Tan, Rachel E Clarke, et al.Nature Reviews. Nephrology|November 11, 2015
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney diseaseMerlin C Thomas, Mark E Cooper, Paul ZimmetCurrent Hypertension Reports|September 3, 2004
Antiproteinuric effect of RAS blockade: new mechanismsMarkus Lassila, Mark E Cooper, Karin Jandeleit-DahmExpert Opinion on Emerging Drugs|September 4, 2008
Agents in development for the treatment of diabetic nephropathySu-Yen Goh, Mariusz Jasik, Mark E CooperKidney International|December 9, 2023
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammationKarly C Sourris, Yi Ding, Scott S Maxwell, et al.Human Mutation|July 23, 2011
New insights into the pathogenesis of Beckwith-Wiedemann and Silver-Russell syndromes: contribution of small copy number variations to 11p15 imprinting defectsJulie Demars, Sylvie Rossignol, Irène Netchine, et al.Genome Research|September 6, 2011
Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cellsLuciano Pirola, Aneta Balcerczyk, Richard W Tothill, et al.Expert Opinion on Investigational Drugs|September 13, 2002
Advanced glycation end products and diabetic complicationsAlan W Stitt, Alicia J Jenkins, Mark E CooperPageof 54